Genetically modified allergens

Immunology and Allergy Clinics of North America

Volumn 24, Issue 4 SPEC. ISS., 2004, Pages 727-738

  Niederberger, Verena ^a   Valenta, Rudolf ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; B LYMPHOCYTE ANTIGEN; BEE VENOM; BIRCH POLLEN ALLERGEN; GRASS POLLEN EXTRACT; POLLEN ANTIGEN; RECOMBINANT ANTIGEN; T LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG; VACCINE;

ALLERGENICITY; ALLERGY; ANAPHYLAXIS; BIRCH; CLINICAL TRIAL; DNA MODIFICATION; DRUG EFFICACY; DRUG SAFETY; GENETIC ENGINEERING; HUMAN; IMMUNOGENICITY; IMMUNOTHERAPY; MOLECULAR BIOLOGY; NONHUMAN; POLLEN ALLERGY; PRIORITY JOURNAL; REVIEW; SENSITIZATION; SIDE EFFECT; SYSTEMIC DISEASE;

EID: 4944248354     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.iac.2004.06.009     Document Type: Review

References (72)

1. B. Wüthrich, C. Schindler, P. Leuenberger, and U. Ackermann-Liebrich Prevalence of atopy and pollinosis in the adult population of Switzerland (SAPALDIA study): Swiss Study on Air Pollution and Lung Diseases in Adults Int Arch Allergy Immunol 106 1995 149 156
2. J. Bousquet, R.F. Lockey, and H.J. Malling Allergen immunotherapy: therapeutic vaccines for allergic diseases: a WHO position paper J Allergy Clin Immunol 102 1998 558 562
3. L. Noon Prophylactic inoculation of hay-fever Lancet 1 1911 1572 1573
4. R.F. Sledge Treatment of hay-fever with alum-precipitated pollen US Naval Med Bull 36 1938 18 25
5. N.A. Attallah, and A.H. Sehon Isolation of haptenic material from ragweed pollen Immunochemistry 6 1969 609 619
6. D.G. Marsh, L.M. Lichtenstein, and D.H. Campbell Studies on "allergoids" prepared from naturally occurring allergens: I. Assay of allergenicity and antigenicity of formalinized rye group I component Immunology 18 1970 705 722
7. A. Malley, L. Baecher, B. Mackler, and F. Periman Further characterization of a low molecular weight allergen fragment isolated from the green pea Clin Exp Immunol 25 1976 159 164
8. W.Y. Lee, and A.H. Sehon Abrogation of reaginic antibodies with modified allergens Nature 267 1977 618 619
9. A. Litwin, A.J. Pesce, and J.G. Michael Regulation of the immune response to allergens by immunosuppressive allergenic fragments: 1. Peptic fragments of honey bee venom phospholipase A2 Int Arch Allergy Appl Immunol 87 1988 361 366
10. K.T. HayGlass, and B.P. Stefura Anti-interferon γ treatment blocks the ability of glutaraldehyde-polymerized allergens to inhibit specific IgE responses J Exp Med 173 1991 279 285
11. B. Trivedi, C. Valerio, and J.E. Slater Endotoxin content of standardized allergen vaccines J Allergy Clin Immunol 111 2003 777 783
12. M.J. Van der Veen, M. Mulder, A.M. Witteman, R. van Ree, R.C. Aalberse, and H.M. Jansen False-positive skin prick test responses to commercially available dog dander extracts caused by contamination with house dust mite J Allergy Clin Immunol 98 1996 1028 1034
13. N. Mothes, M. Heinzkill, K.J. Drachenberg, W.R. Sperr, M.T. Krauth, and Y. Majlesi Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvant vaccine: reduced seasonally boosted IgE production and inhibition of basophil histamine release by blocking antibodies Clin Exp Allergy 33 2003 1198 1208
14. M. van Hage-Hamsten, and R. Valenta Specific immunotherapy†"the induction of new IgE specificities? Allergy 57 2002 375 378
15. R. Movérare, L. Elfman, E. Vesterinen, T. Metso, and T. Haahtela Development of new IgE specifities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP system Allergy 57 2002 423 430
16. T. Ball, W.R. Sperr, P. Valent, J. Lidholm, S. Spitzauer, and C. Ebner Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy Eur J Immunol 29 1999 2026 2036
17. R. Valenta, T. Ball, M. Focke, B. Linhart, N. Mothes, and V. Niederberger Immunotherapy of allergic disease Adv Immunol 82 2004 105 153
18. T.P. King, and M.D. Spangfort Structure and biology of stinging insect venom allergens Int Arch Allergy Immunol 123 2000 99 106
19. H. Breiteneder, and C. Ebner Molecular and biochemical classification of plant-derived food allergens Int Arch Allergy Immunol 106 2000 27 36
20. R. Rodriguez, M. Villalba, R.I. Monsalve, and E. Batanero The spectrum of olive pollen allergens Int Arch Allergy Immunol 125 2001 185 195
21. W.R. Thomas, W.A. Smith, B.J. Hales, K.L. Mills, and RM. O'Brien Characterization and immunobiology of house dust mite allergens Int Arch Allergy Immunol 129 2002 1 18
22. V.P. Kurup, H.D. Shen, and H. Vijay Immunobiology of fungal allergens Int Arch Allergy Immunol 129 2002 181 188
23. K. Andersson, and J. Lidholm Characteristics and immunobiology of grass pollen allergens Int Arch Allergy Immunol 130 2003 87 107
24. K.H. Roux, S.S. Teuber, and S.K. Sathe Tree nut allergens Int Arch Allergy Immunol 131 2003 234 244
25. P. Colombo, A. Bonura, M. Costa, V. Izzo, R. Passantino, and G. Locorotondo The allergens of Parietaria Int Arch Allergy Immunol 130 2003 173 179
26. R. Valenta, S. Vrtala, M. Focke-Tejkl, A. Bugajska-Schretter, T. Ball, and A. Twardosz Genetically engineered and synthetic allergen derivatives: candidates for vaccination against type I allergy Biol Chem 380 1999 815 824
27. R. Valenta, and D. Kraft From allergen structure to new forms of allergen-specific immunotherapy Curr Opin Immunol 14 2002 718 727
28. R. Valenta, J. Lidholm, V. Niederberger, B. Hayek, D. Kraft, and H. Gronlund The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT) Clin Exp Allergy 29 1999 896 904
29. R. Valenta, S. Vrtala, C. Ebner, D. Kraft, and O. Scheiner Diagnosis of grass pollen allergy with recombinant timothy grass (Phleum pratense) pollen allergens Int Arch Allergy Immunol 97 1992 287 294
30. V. Niederberger, G. Pauli, H. Grönlund, R. Fröschl, H. Rumpold, and D. Kraft Recombinant birch pollen allergens (rBet v 1 and rBet v 2) contain most of the IgE epitopes present in birch, alder, hornbeam, hazel, and oak pollen: a quantitative IgE inhibition study with sera from different populations J Allergy Clin Immunol 102 1998 579 591
31. V. Niederberger, S. Laffer, R. Fröschl, D. Kraft, H. Rumpold, and S. Kapiotis IgE antibodies to recombinant pollen allergens (Phl p 1, Phl p 2, Phl p 5, and Bet v 2) account for a high percentage of grass pollen-specific IgE J Allergy Clin Immunol 101 1998 258 264
32. L. Kazemi-Shirazi, V. Niederberger, B. Linhart, J. Lidholm, D. Kraft, and R. Valenta Recombinant marker allergens: diagnostic gatekeepers for the treatment of allergy Int Arch Allergy Immunol 127 2002 259 268
33. J. Bousquet, W.M. Becker, A. Jejjaoui, I. Chanal, B. Lebel, and H. Dhivert Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple-pollen species: II. Efficacy of a double-blind, placebo-controlled, specific immunotherapy with standardized extracts J Allergy Clin Immunol 88 1991 43 53
34. R. Hiller, S. Laffer, C. Harwanegg, M. Huber, W.M. Schmidt, and A. Twardosz Microarrayed allergen-molecules: diagnostic gatekeepers for allergy treatment FASEB J 16 2002 414 416
35. R. Suck, A. Nandy, B. Weber, M. Stock, H. Fiebig, and O. Cromwell Rapid method for arrayed investigation of IgE-reactivity profiles using natural and recombinant allergens Allergy 57 2002 821 824
36. C. Harwanegg, S. Laffer, R. Hiller, M.W. Mueller, D. Kraft, and S. Spitzauer Microarrayed recombinant allergens for diagnosis of allergy Clin Exp Allergy 33 2003 7 13
37. R. Valenta The future of antigen-specific immunotherapy of allergy Nat Rev Immunol 2 2002 446 453
38. G.F. Hoyne, R.E. O'Hehir, D.C. Wraith, W.R. Thomas, and J.R. Lamb Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naïve and sensitized mice J Exp Med 178 1993 1783 1788
39. T.J. Briner, M.C. Kuo, K.M. Keating, B.L. Rogers, and J.L. Greenstein Peripheral T-cell tolerance induces in naïve and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I Proc Natl Acad Sci U S A 90 1993 7608 7612
40. F.E. Simons, M. Imada, Y. Li, W.T. Watson, and K.T. HayGlass Fel d 1 peptides: effects on skin tests and cytokine synthesis in cat-allergic human subjects Int Immunol 8 1996 1937 1945
41. J. Pene, A. Desroches, L. Paradis, B. Lebel, M. Farce, and C.F. Nicodemus Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripherial blood T cells of patients allergic to cats J Allergy Clin Immunol 102 1998 751 758
42. U. Müller, C.A. Akdis, M. Fricker, M. Akdis, T. Blesken, and F. Bettens Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom J Allergy Clin Immunol 101 1998 747 754
43. B.M. Haselden, A.B. Kay, and M. Larché Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions J Exp Med 189 1999 1885 1894
44. L.G. Oldfield, A.B. Kay, and M. Larché Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects J Immunol 167 2001 1734 1739
45. W.L.G. Oldfield, M. Larché, and A.B. Kay Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised control trial Lancet 360 2002 47 53
46. T. Ball, T. Fuchs, W.R. Sperr, P. Valent, L. Vangelista, and D. Kraft B cell epitopes of the major timothy grass pollen allergen, Phl p 1, revealed by gene fragmentation as candidates for immunotherapy FASEB J 13 1999 1277 1290
47. M. Focke, V. Mahler, T. Ball, W.R. Sperr, Y. Majlesi, and P. Valent Nonanaphylactic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination FASEB J 15 2001 2042 2044
48. E. Jensen-Jarolim, A. Leitner, H. Kalchhauser, A. Zurcher, E. Ganglberger, and B. Bohle Peptide mimotopes displayed by phage inhibit antibody binding to Bet v 1, the major birch pollen allergen, and induce specific IgG response in mice FASEB J 12 1998 1635 1642
49. S. Flicker, and R. Valenta Renaissance of the blocking antibody concept in type I allergy Int Arch Allergy Immunol 132 2003 13 24
50. S. Vrtala, K. Hertenlehner, L. Vangelista, A. Pastore, H.G. Eichler, and W.R. Sper Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy J Clin Invest 99 1997 1673 1681
51. G. Pauli, A. Purohit, J.P. Oster, F. De Blay, S. Vrtala, and V. Niederberger Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild-type by skin prick and intradermal testing: results obtained in a French population Clin Exp Allergy 30 2000 1076 1084
52. M. van Hage-Hamsten, M. Kronqvist, O. Zetterstrom, E. Johansson, V. Niederberger, and S. Vrtala Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season J Allergy Clin Immunol 104 1999 969 977
53. B. Tang, B. Banerjee, P.A. Greenberger, J.N. Fink, K.J. Kelly, and V.P. Kurup Antibody binding of deletion mutants of Asp f 2, the major Aspergillus fumigatus allergen Biochem Biophys Res Commun 270 2000 1128 1135
54. A. Twardosz, B. Hayek, S. Seiberler, L. Vangelista, L. Elfman, and H. Grönlund Molecular characterization, expression in Escherichia coli, and epitope analysis of a two EF-hand calcium-binding birch pollen allergen, Bet v 4 Biochem Biophys Res Commun 239 1997 197 204
55. B. Hayek, L. Vangelista, A. Pastore, W.R. Sperr, P. Valent, and S. Vrtala Molecular and immunologic characterization of a highly cross-reactive two EF-hand calcium-binding alder pollen allergen, Aln g 4: structural basis for calcium-modulated IgE recognition J Immunol 161 1998 7031 7039
56. S. Vrtala, S. Fischer, M. Grote, L. Vangelista, A. Pastore, and W.R. Sperr Molecular, immunological, and structural characterization of Phl p 6, a major allergen and P-particle-associated protein from Timothy grass (Phleum pratense) pollen J Immunol 163 1999 5489 5496
57. E. Tamborini, S. Faccini, J. Lidholm, M. Svensson, A. Brandazza, and R. Longhi Biochemical and immunological characterization of recombinant allergen Lol p 1 Eur J Biochem 249 1997 886 894
58. T. Zeiler, A. Taivainen, M. Rytkonen, J. Rautiainen, H. Karjalainen, and R. Mantyjarvi Recombinant allergen fragments as candidate preparations for allergen immunotherapy J Allergy Clin Immunol 100 1997 721 727
59. S. Vrtala, K. Hirtenlehner, M. Susani, M. Akdis, F. Kussebi, and C.A. Akdis Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen, Bet v 1 FASEB J 15 2001 2045 2047
60. S. Korematsu, Y. Tanaka, S. Hosoi, S. Koyanagi, T. Yokota, and B. Mikami C8/119S mutation of major mite allergen Der f-2 leads to degenerate secondary structure and molecular polymerization and induces postent and exclusive Th1 cell differentiation J Immunol 165 2000 2895 2902
61. I. Swoboda, N. De Weerd, P.L. Bhalla, V. Niederberger, W.R. Sperr, and P. Valent Mutants of the ryegrass pollen allergen, Lol p 5, with reduced IgE-binding capacity: candidates for grass-pollen-specific immunotherapy Eur J Immunol 32 2002 270 280
62. F. Ferreira, C. Ebner, B. Kramer, G. Casari, P. Briza, and A.J. Kungl Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential use of hypoallergenic variants for immunotherapy FASEB J 12 1998 231 242
63. A.M. Smith, and M.D. Chapman Reduction of IgE binding to allergen variants generated by site-directed mutagenesis: contribution of disulfide bonds to the antigenic structure of the major house dust mite allergen Der p 2 Mol Immunol 33 1996 399 405
64. T. Takai, T. Yokota, M. Yasue, C. Nishiyama, T. Yuuki, and A. Mori Engineering of the major house dust mite allergen Der f 2 for allergen-specific immunotherapy Nat Biotechnol 15 1997 754 758
65. S. Olsson, M. van Hage-Hamsten, and P. Whitley Contribution of disulphide bonds to antigenicity of Lep d 2, the major allergen of the dust mite Lepidoglyphus destructor Mol Immunol 35 1998 1017 1023
66. E. Engel, K. Richter, G. Obermeyer, P. Briza, A.J. Kungl, and B. Simon Immunological and biological properties of Bet v 4, a novel birch pollen allergen with two EF-hand calcium-binding domains J Biol Chem 272 1997 28630 28637
67. B. Linhart, B. Jahn Schmid, P. Verdino, W. Keller, C. Ebner, and D. Kraft Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicity FASEB J 16 2002 1301 1303
68. B. Linhart, and R. Valenta Vaccine engineering improved by hybrid technology Int Arch Allergy Immunol 134 2004 324 331
69. O. Arquint, A. Helbling, R. Crameri, F. Ferreira, M. Breitenbach, and W.J. Pichler Reduced in vivo allergenicity of Bet v 1 d isoform, a natural component of birch pollen J Allergy Clin Immunol 104 1999 1239 1243
70. M. van-Hage Hamsten, E. Johansson, A. Roquet, C. Peterson, M. Andersson, and L. Greiff Nasal challenges with recombinant derivatives of the major birch pollen allergen Bet v 1 induce fewer symptoms and lower mediator release than rBet v 1 wild-type in patients with allergic rhinitis Clin Exp Allergy 32 2002 1448 1453
71. A. Nopp, G. Hallden, J. Lundahl, E. Johansson, S. Vrtala, and R. Valenta Comparison of inflammatory responses to genetically engineered hypoallergenic derivatives of the major birch pollen allergen Bet v 1 and to recombinant Bet v 1 wild type in skin chamber fluids collected from birch pollen allergic patients J Allergy Clin Immunol 106 2000 101 109
72. Niederberger V., Horak F., Vrtala S., Spitzauer S., Krauth M.T., Valent P., et al. Development of a novel allergy vaccine: Genetically modified allergens prevent progression of allergic disease. Proc Natl Acad Sci USA, in press